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Abstract: Non-alcoholic fatty liver disease (NAFLD) covers a spectrum of disorders ranging from
simple steatosis (non-alcoholic fatty liver, NAFL) to non-alcoholic steatohepatitis (NASH) and
cirrhosis. NAFL increases the risk of liver fibrosis. If the liver is fatty due to causes of insulin
resistance such as obesity and physical inactivity, it overproduces glucose and triglycerides leading
to hyperinsulinemia and a low high-density lipoprotein (HDL) cholesterol concentration. The
latter features predispose to type 2 diabetes and cardiovascular disease (CVD). Understanding the
impact of nutritional modulation of liver fat content and insulin resistance is therefore of interest
for prevention and treatment of NAFLD. Hypocaloric, especially low carbohydrate ketogenic diets
rapidly decrease liver fat content and associated metabolic abnormalities. However, any type of
caloric restriction seems effective long-term. Isocaloric diets containing 16%–23% fat and 57%–65%
carbohydrate lower liver fat compared to diets with 43%–55% fat and 27%–38% carbohydrate. Diets
rich in saturated (SFA) as compared to monounsaturated (MUFA) or polyunsaturated (PUFA) fatty
acids appear particularly harmful as they increase both liver fat and insulin resistance. Overfeeding
either saturated fat or carbohydrate increases liver fat content. Vitamin E supplementation decreases
liver fat content as well as fibrosis but has no effect on features of insulin resistance.
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1. Introduction
NAFLD Definitions. Non-alcoholic fatty liver disease (NAFLD) is defined as steatosis (over 5%
to 10% of hepatocytes have macroscopic steatosis) [1], which is not due to excess use of alcohol
(defined in the most recent guideline from American Association for the Study of Liver Diseases as
alcohol consumption exceeding 21 drinks on average per week in men and 14 drinks in women) [2],
or other conditions as determined by careful family and medical history, and laboratory tests to
exclude at least steatosis due to viral and autoimmune causes and iron overload [2]. NAFLD is
usually asymptomatic and most patients have normal transaminases (ALT <30–40 U/L for men and
<20–30 U/L for women) [3,4] although NAFLD is the most common cause of incidentally discovered
elevated liver function tests [5]. Some patients with NAFLD have non-alcoholic steatohepatitis
(NASH), which can only be diagnosed by a liver biopsy. NASH is characterized in addition to
steatosis by ballooning necrosis in the vicinity of steatotic hepatocytes, mild inflammation and
possibly fibrosis [6]. Fibrosis is staged on a scale from 0 to 4, where 4 is cirrhosis [6]. While NAFLD
is as common as the metabolic syndrome (MetS), the prevalence estimates of NASH range from 3%
to 6% [7,8].
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Heterogeneity of NAFLD. Although NAFLD is commonly observed in insulin-resistant obese
and sometimes insulin-resistant non-obese subjects with the MetS (“Metabolic NAFLD”) (Figure 1),
at least two common genetic forms of NAFLD also exist. An allele in PNPLA3 (rs738409[G], encoding
I148M, prevalence 30%–50% worldwide) increases liver fat (“PNPLA3 NAFLD”) and the risk of
hepatic inflammation and fibrosis, cirrhosis and hepatocellular carcinoma (HCC) [9–12]. “PNPLA3
NAFLD” is not associated with insulin resistance [10,13]. Another fairly common polymorphism,
an E167K variant in (E167K) in TM6SF2 (prevalence 15%) also confers susceptibility to NAFLD
(“TM6SF2 NAFLD”) [14]. Carriers with “TM6SF2 NAFLD” are at increased risk of NASH but are
not insulin-resistant and their circulating concentrations of triglycerides are normal or subnormal
rather than increased [14,15]. Hepatic knockdown of TM6SF2 decreases very low-density lipoprotein
(VLDL) secretion [14,16].
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Figure 1. Pathophysiology of “Metabolic NAFLD”, which causes and consequences resemble those 
of the insulin resistance/metabolic syndrome (MetS). Overeating and physical inactivity predispose 
to both conditions. Excess glucose, fructose and amino acids are converted to triglyceride (TG) in the 
liver via de novo lipogenesis (DNL), which pathway is increased in NAFLD [17]. Alterations in gut 
microbiota in obesity increase gut permeability to bacterial components such as lipopolysaccharide 
(LPS), which may contribute to inflammation in both adipose tissue and the liver [18]. Overeating 
leads to adipose tissue expansion, hypoxia, increased fibrosis and cell death. Dead adipocytes 
surrounded by macrophages, which produce cytokines such as tumor-necrosis alpha and 
chemokines such as monocyte chemoattractant protein-1. This impairs the ability of insulin to 
inhibit lipolysis i.e., inhibit release of free fatty acids (FFA) and leads to deficiency of the insulin-
sensitizing cytokine adiponectin. The latter two changes promote synthesis of intrahepatocellular 
TG. The ability of insulin to suppress glucose and VLDL production is impaired resulting in mild 
hyperglycemia and hyperinsulinemia, hypertriglyceridemia (TG↑) and a low HDL cholesterol 
concentration (HDL chol↓). The fatty liver also overproduces many other factors such as the liver 
enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-
glutamyltransferase (GGT), C-reactive protein (CRP) and coagulation factors [13]. 
While the PNPLA3 or TM6SF2 variants increase liver fat content and the risk of NASH, they do 
not increase the risk of type 2 diabetes or cardiovascular disease (CVD), consistent with lack of 
insulin resistance. This implies that the objective of treatment of patients with “PNPLA3 NAFLD” 
and TM6SF2 NAFLD’ is to prevent liver disease rather than metabolic complications. However, the 
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While the PNPLA3 or TM6SF2 variants increase liver fat content and the risk of NASH, they
do not increase the risk of type 2 diabetes or cardiovascular disease (CVD), consistent with lack of
insulin resistance. This implies that the objective of treatment of patients with “PNPLA3 NAFLD”
and TM6SF2 NAFLD’ is to prevent liver disease rather than metabolic complications. However, the
same person may have “Metabolic NAFLD” and NAFLD attributable to genetic variants [15]. The
etiology of NAFLD might impact the response of the liver to dietary interventions (vide infra).
Significance. Patients with NAFLD have an increased risk of mortality from CVD, cirrhosis
and hepatocellular carcinoma (HCC) [19]. Recent prospective studies with paired liver biopsies
contradicted the old dogma that NAFL is benign by showing that NAFL can progress to NASH and
clinically significant fibrosis [8]. A recent meta-analysis of 411 patients with biopsy-proven NAFLD
defined the average rate of progression. The rate of 1 stage fibrosis progression was 14.3 years for
NAFL and 7.1 years for patients with NASH [20]. Given this slow rate of progression and lack
of approved pharmacotherapies for NAFLD, there is abundant time for lifestyle changes to impact
progression of NAFLD.
NAFLD and insulin resistance. The liver is the site of production of two key components of
the insulin resistance/MetS, fasting serum glucose and very-low density lipoprotein (VLDL), which
contains most of circulating triglycerides. In subjects with NAFLD attributable to being overweight
and inactive (“Metabolic NAFLD”), the ability of insulin to normally suppress production of glucose
and VLDL is impaired [21,22]. Hyperglycemia stimulates insulin secretion and thereby induces
hyperinsulinemia (Figure 1). The high concentration of VLDL leads to lowering of high-density
lipoprotein (HDL) cholesterol and to generation of small dense LDL particles, which are known to be
highly atherogenic (see [23] for review). The liver, once fatty, also overproduces many other markers
of cardiovascular risk such as C-reactive protein and coagulation factors [13] (Figure 1).
The ensuing review is focused on analyzing studies comparing effects of different diets on
liver fat content and insulin sensitivity in the face of a similar total caloric content. The studies are
subgrouped based on their caloric content (isocaloric/hypocaloric/hypercaloric). Studies comparing
low fat/high carbohydrate to high fat/low carbohydrate diets are shown in Table 1 and studies
comparing effects of different types of sugars on liver fat content and insulin sensitivity in Table 2.
The influence of dietary fat on liver fat accumulation has recently been analyzed in an excellent
review [24].
Table 1. Studies comparing effects of low fat-high carbohydrate and high fat-low carbohydrate on
liver fat and insulin sensitivity.
N BMI(kg/m2)
Age
(Years) Duration Design Cal % Fat % Carb
Liver Fat
(%)
Before-After
Insulin
Sensitivity
Method Change
Year of
Reference
10 33 43 2 weeks C ISO
16% 61%
56% 31%
10–8 *
10–13
fS-Ins Improved
Worsened
2005 [25]
20 29 34 3 weeks P ISO
20% 65% 4.0–3.5 * Clamp NS
NS
2011 [26]55% 30% 2.2–2.6
61 31 30–65 10weeks P ISO
40% a 39% 3.2–2.3 * fS-Ins NS
Worsened
2012 [27]
43% b 40% 3.2–3.5
45 30 35–70 8 weeks P ISO
28% 53% 17.7–16.1 fS-Ins NS
NS
2012 [28]42% c 40% 7.4–5.2 Ó*
35 27 69 4 weeks P ISO
23% 57% 2.2–1.7Ó fS-Ins NS
NS
2013 [29]43% 38% 1.2–1.6
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12 32 55 6 weeks C ISO
21% d 49% 11.2–10.0 Clamp NS *
Improved 2013 [30]44% e 34% 14.2–8.6Ó *
22 37 44 11weeks P HYPO
20% 65%
75% 10%
11.2–6.2Ó
12.4–7.7Ó
fS-Ins Improved *
Improved 2009 [31]
18 35 45 2 weeks P HYPO
34% 50% 19–8.6Ó * fS-Ins NS
NS
2011 [32]59% 8% 22–15.8Ó
102 32 45 6months P HYPO
fS-Ins Improved
Improved 2011 [33]“reduced fat”“reduced carb”
9.6–5.6Ó
7.6–4.0Ó
39 23 25 7 days P HYPER
+fructose 12–14h Ò fS-Ins NS
NS
2010 [34]
+fat 11–21h Ò
39 18–27 20–38 7 weeks P HYPER
40% f 43% 0.75–0.79 fS-Ins NS
NS
2014 [35]36% g 48% 0.96–1.5 *
Abbreviations: N = number of completers, BMI = body mass index, yrs = years, wks = weeks, mos = months,
C = crossover, P = parallel, Cal = caloric content relative to baseline diet, ISO = isocaloric, HYPO = hypocaloric,
HYPER = hypercaloric, % Fat % Carb = % fat and % carbohydrate. Ò Significant increase, Ó significant
decrease before vs. after, * significant difference in change between the two different diets, fS-Ins = fasting
serum insulin, Clamp = euglycemic hyperinsulinemic insulin clamp technique. a = 10% SFA, 13% POLY;
b = 20% SFA, 8% POLY; c enriched with MONO, saturated fat as in control arm; d 36% SFA/39% MONO/24%
POLY; e 31% SFA/51% MONO/18% POLY; f 11% SFA and 13% POLY; g 16% SFA and 4% POLY, h Units for
liver fat mmol/kg. NS = no significant change. Changes in liver fat in the table calculated based on mean
changes. +fructose = addition of 3.5 grams/day of fructose/kg fat free mass, +fat = addition of 30% of total
calories as fat.
Table 2. Effects of fructose as compared to other carbohydrates on liver fat and insulin sensitivity.
N BMI(kg/m2)
Age
(Years) Duration Design Cal
Fructose Diet Other
CARB Diet
Liver Fat
(%)
Before-After
Insulin
Sensitivity
Method Change
Year of
Reference
32 29 34 2 weeks P ISO
FRU 25% b 7.2–7.5 fS-Ins Worsened
NS c
2013 [36]
GLU 25% b 8.0–7.9
11 75 kg b 25 7 days C HYPER
FRU 35% b 2.1–3.2Ò fS-Ins NS
NS
2010 [37]
GLU 35% b 2.1– 3.3Ò
20 25 30 10weeks P HYPER
FRU +600 cal/day 1.3–1.8 fS-Ins NS
NS
2012 [38]GLU +600 cal/day 1.6–2.1
22 32 39 6months P HYPER
SSB +430 cal/day 3.7–5.0Ò* fS-Ins NS
NS
2012 [39]Milk +454 cal/day 12.7–11.6
64 27 42
10
weeks P HYPER
HFCS 8%–30% b 11.8–13.7 fS-Ins NS
NS 2013 [40]SUCROSE 8%–30% b 14.9–13.0
32 29 34 2 weeks P HYPER
FRU +25% b 7.2–8.9Ò fS-Ins NS
NS
2013 [36]
GLU +25% b 8.0–10.1Ò
28 22 23
6–7
days P HYPER
FRU 3 g/kg day
GLU 3 g/kg day
9.0–18.5Ò
12.9–16.1
fS-Ins Worsened
NS
2013 [41]
Abbreviations: N = number of completers, BMI = body mass index, yrs = years, wks = weeks, mos = months,
d = day, C = crossover, P = parallel, Cal = caloric content relative to baseline diet, FRU = fructose, HFCS = high
fructose corn syrup, GLU = glucose, NS = no significant change (before vs. after diet), ISO = isocaloric, HYPER
= hypercaloric, SSB = sugar sweetened beverage, Ò Significant increase after vs. before, * significant difference
in change between the two diets, fS-Ins = fasting serum insulin, Clamp = euglycemic hyperinsulinemic insulin
clamp technique. a = body weight, b = % of total energy intake, c NS = no significant change. Changes in liver
fat in the table calculated based on mean changes.
2. Effect of Different Diets on NAFLD and Insulin Sensitivity
Overall, as shown by Figure 2, the energy content of the diet is the most important factor
influencing liver fat content, which is why weight loss is recommended to all overweight or obese
patients with NAFLD [2] Given that conventional hypocaloric diets are unable to achieve persistent
weight loss in morbidly obese patients, bariatric surgery is becoming increasingly important in the
management of NAFLD. Weight loss following bariatric surgery induces improvements in steatosis,
necroinflammation and fibrosis and insulin resistance. NASH is not a contraindication for surgery
unless complicated by cirrhosis or portal hypertension (see [42–45] for reviews).
9130
Nutrients 2015, 7, 9127–9138
Nutrients 2015, 7, page–page 
6 
2. Effect of Different Diets on NAFLD and Insulin Sensitivity 
Overall, as shown by Figure 2, the energy content of the diet is the most important factor 
influencing liver fat content, which is why weight loss is recommended to all overweight or obese 
patients with NAFLD [2] Given that conventional hypocaloric diets are unable to achieve persistent 
weight loss in morbidly obese patients, bariatric surgery is becoming increasingly important in the 
management of NAFLD. Weight loss following bariatric surgery induces improvements in steatosis, 
necroinflammation and fibrosis and insulin resistance. NASH is not a contraindication for surgery 
unless complicated by cirrhosis or portal hypertension (see [42–45] for reviews). 
 
Figure 2. Effect of dietary composition on liver fat content, expressed as relative change from 
baseline measured by proton magnetic resonance spectroscopy (1H-MRS). Diets comparing 
isocaloric low fat/high carbohydrate (Low Fat High Carb) to high fat/low-carbohydrate (High Fat 
Low Carb) diets (upper panel on the left, 1 = [25], 2 = [26], 3 = [29]), isocaloric low saturated fat/high 
polyunsaturated fat (Low SFA High PUFA) to high saturated/low polyunsaturated fat (High SFA 
Low PUFA) or isocaloric high monounsaturated (High MUFA) to low monounsaturated fat (Low 
MUFA) (upper panel on the right, 4 = [27], 5 = [28], 6 = [30]) diets. The bottom panels depict effects of 
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[32], 9 = [33]) and hypercaloric Low Fat High Carb vs. High Fat Low Carb (10 = [34]) and High PUFA 
Low SFA vs. Low PUFA High SFA (11 = [35]) diets on liver fat content. 
Genetic etiology of NAFLD may influence the response to a hypocaloric diet. We observed a 
greater reduction in liver fat in response to a six-day ketogenic diet in subjects homozygous for the 
PNPLA3 I148M variant as compared to non-carriers [46]. This finding was recently confirmed in a 
larger post hoc analysis of 154 patients [47]. In this study, liver fat content measured by 1H-MRS 
decreased significantly and 3-fold more in subjects with the GG as compared to CC genotype 
(11.3% vs. 3.7%). 
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Figure 2. Effect of dietary composition on liver fat content, expressed as relative change from baseline
measured by proton magnetic resonance spectroscopy (1H-MRS). Diets comparing isocaloric low
fat/high carbohydrate (Low Fat High Carb) to high fat/low-carbohydrate (High Fat Low Carb) diets
(upper panel on the left, 1 = [25], 2 = [26], 3 = [29]), isocaloric low saturated fat/high polyunsaturated
fat (Low SFA High PUFA) to high saturated/low polyunsaturated fat (High SFA Low PUFA) or
isocaloric high monounsaturated (High MUFA) to low monounsaturated fat (Low MUFA) (upper
panel on the right, 4 = [27], 5 = [28], 6 = [30]) diets. The bottom panels depict effects of hypocaloric
Low Fat High Carb compared to High Fat Low Carb diets (panel on the left, 7 = [31], 8 = [32], 9 = [33])
and hypercaloric Low Fat High Carb vs. High Fat Low Carb (10 = [34]) and High PUFA Low SFA vs.
Low PUFA High SFA (11 = [35]) diets on liver fat content.
Genetic etiology of AFLD ay influence the response to a hypocaloric diet. e observed a
greater reduction in liver fat in response to a six-day ketogenic diet in subjects ho ozygous for the
P PLA3 I148 variant as co pared to non-carriers [46]. This finding was recently confirmed in
a larger post hoc analysis of 154 patients [47]. In this study, liver fat content easured by 1 - RS
decreased significantly and 3-fold ore in subjects ith the GG as co pared to CC genotype
(11.3 vs. 3.7 ).
Isocaloric co parisons (Figure 2, Table 1). In three of the studies sho n in Table 1, a lo fat
(16 –23 of total calories)–high carbohydrate (57 –65 ) diet as co pared to a lo carbohydrate
(31 –38 )–high fat (43 –56 ) diet. uite consistently, liver fat content decreased during the lo
fat-high carbohydrate diet and increased during the high fat-lo carbohydrate diet (Figure 2). The
high fat rather than the low carbohydrate component in the diet is the likely cause of the increase in
liver fat since low carbohydrate diets seem particularly effective in reducing liver fat (vide infra).
In the isocaloric comparisons of a high fat–low carbohydrate vs. a low fat–high carbohydrate
diets, there were no convincing changes in insulin sensitivity. However, the studies were small and
hepatic insulin sensitivity was not assessed directly.
Hypocaloric comparisons (Figure 2, Table 1). Even small amounts of weight loss decrease liver
fat content. For example, two to six days of a hypocaloric diet (´1000 cal/day) decreases liver
fat by 30%–45% in the face of trivial amounts of weight loss [31,46]. Two studies have compared
changes in liver fat during ketogenic low-carbohydrate and standard hypocaloric diets in the face of
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similar decrease in body weight. In these studies lasting two days and two weeks, the ketogenic diet
decreased liver fat content more than the standard hypocaloric diet [31,32]. However, in the study of
Kirk et al [31], repeat study of the subjects after 11 weeks no longer showed a significant difference in
the decrease in liver fat content (Table 1). Patients are commonly placed on a hypocaloric diet prior
to bariatric surgery to reduce liver volume. Low-carbohydrate ketogenic diets decrease liver volume
more than standard hypocaloric diets, most likely because low carbohydrate diets rapidly deplete
liver glycogen [48].
Hypercaloric comparisons (Figure 2, Table 1). Rosqvist et al. [35] compared a diet enriched with
SFAs at the expense of PUFAs to a diet rich in PUFAs but poor in SFAs. The extra calories were
served as similar looking muffins. Macronutrient composition of the diets was comparable. After
seven weeks, weight gain was identical in both groups (1.6 kg) but liver fat content had increased in
the high SFA-low PUFA group but not in the other group (Figure 2). In the other study including
39 subjects, seven days of high fat overfeeding (30% caloric excess from fat) increased liver fat
content by 86% while fructose overfeeding only increased liver fat by 16% [34]. The difference in
the increments in liver fat was not statistically significant.
3. Effect of Type of Fat on NAFLD and Insulin Sensitivity
High SFA–Low PUFA vs. Low SFA–High PUFA. In the largest of the isocaloric studies [27],
macronutrient composition was maintained essentially unchanged but the quality of the fat differed.
Liver fat content decreased during the diet high in PUFA and low in SFA compared to the high
SFA–low PUFA diet. This suggests that either SFAs or PUFAs regulate liver content. Fasting insulin
increased in the high SFA-low PUFA group and remained unchanged in the high PUFA-low SFA
group (Table 1). This result supports previous data such as the KANWU study in 162 subjects
showing that isocaloric substitution of dietary SFA for MUFA for three months impairs insulin
sensitivity and lowers LDL cholesterol [49]. The impairment in insulin sensitivity was due to the
SFA rather than the MUFA diet, consistent with several smaller studies [50].
High MUFA. Two isocaloric studies compared the effect of increasing total fat content using
mainly MUFAs [28,30]. Although total fat content was higher both in the study of Bozzetto et al.
(42% vs. 28%) [28] and the study of Ryan et al. (44% vs. 21%) [30], liver fat content decreased with the
diets enriched with MUFAs. However, the lower carbohydrate content of the MUFA could also have
contributed to the lowering of liver fat content.
As summarized in an extensive review, MUFAs do not impair insulin sensitivity as do SFAs [50].
For example, MUFAs did not affect insulin sensitivity In the “KANWU” study [49] or in the more
recent large 24-week “RISCK” study where subjects were randomized to consume either a high SFA
or a high MUFA diet [51].
4. Effect of Type of Carbohydrate on NAFLD and Insulin Sensitivity
In contrast to glucose, fructose bypasses the rate-limiting step of glycolysis catalyzed by
phosphofructokinase in the liver (see [52] for review). It therefore can provide more substrates for
de novo lipogenesis (DNL) than glucose and could be predicted to increase intrahepatic triglycerides
and VLDL production more than glucose [52]. Five studies have compared effects of fructose or high
fructose corn syrup to glucose or sucrose overfeeding on liver fat content (Table 2). Of these, only
one short-term study found fructose but not glucose to increase liver fat [41]. Fructose did not induce
insulin resistance in any of the studies. Maersk et al. found six months of sugar-sweetened beverage
(SSB) to increase liver fat more than milk [39]. However, milk contains only half as much carbohydrate
as SSB the rest being protein and fat. These data and the systematic review and meta-analysis by
Chung et al. [53] imply that there is not enough evidence to draw conclusions regarding effects of
fructose and HFCS compared to sucrose consumption on NAFLD. However, even if a difference in
changes in liver fat between the fructose and glucose was not demonstrated, excess carbohydrate
calories increased liver fat content in many of the comparative studies as has also been found in high
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sugar overfeeding studies without another carbohydrate comparator arm [34,46,54,55]. Although not
found in studies quantifying liver fat (Table 2), isocaloric fructose (25% of total daily caloric intake for
10 weeks) as compared to glucose consumption has been shown to impair insulin sensitivity [56].
5. Effect of Other Nutritional Interventions on NAFLD and Insulin Sensitivity
Vitamin E. Vitamin E is an antioxidant which, at a dose of 800 IU/day was shown to improve
steatosis, inflammation and ballooning in a 96-week trial in NASH [57]. The vitamin E arm included
84 subjects and placebo arm 83 subjects with NASH but with no diabetes. Vitamin E did not change
insulin sensitivity or lipid concentrations. Vitamin E at a dose of 800 IU/day compared to placebo
has also been shown to resolve NASH in children aged 8–17 years with biopsy-proven NAFLD [58].
6. Mechanisms Underlying Nutritional Modulation of Liver Fat Content in Humans
Fatty acids in intrahepatocellular triglycerides can originate from adipose tissue lipolysis, DNL,
uptake of fatty acids from chylomicron remnants and from fatty acids released during intravascular
hydrolysis of triglyceride-rich lipoproteins [59]. Studies using stable isotopes to trace pathways of
hepatic triglyceride synthesis have shown that both adipose tissue lipolysis and DNL are increased
in NAFLD [17,60–62] (Figure 1).
Nutritional modulation of lipolysis. Short-term fasting lowers glucose and insulin concentrations
and increases the rate of basal lipolysis [46,63,64]. The increase rate of lipolysis, as measured
by a stable isotope glycerol tracer is closely related to decreases in fasting insulin [63]. After an
overnight fast, approximately 40% of the FFA are taken up by the splanchnic bed. These FFA can
be used for ketone body production, oxidation or secreted in VLDL. Over six days of a hypocaloric
low-carbohydrate diet, liver fat decreases despite an increase in lipolysis as FFA as are oxidized and
used for ketone body production rather than stored as triglycerides in the liver [46]. Whether these
changes were due to the decrease in energy content of the diet or the low carbohydrate content is
unclear as very few data comparing effects of different diets on liver fat content and lipolysis are
available. In the study of Haufe et al. comparing low and high carbohydrate hypocaloric diets [33],
fasting FFA increased during the low carbohydrate diet but remained unchanged during the high
carbohydrate diet [33]. As reviewed by Jensen et al., isoenergetic diets do not seem to change basal
FFA flux or oxidation [65].
Nutritional modulation of DNL. Short-term overfeeding with carbohydrate as compared to
fat markedly increases DNL [66,67], which in relative terms is the most increased pathway in
NAFLD [17]. However, in absolute terms, lipolysis is the main source of intrahepatocellular
triglycerides both in normal subjects and those with NAFLD [17]. There are no studies comparing
effects of different diets on liver fat content and DNL.
7. Concluding Remarks
Studies comparing effects of different diets on liver fat content and insulin sensitivity have
included a low number of subjects and lasted a maximum of six months. Nevertheless, some
conclusions seem justified. Hypocaloric diets decrease while overfeeding increases liver fat content.
Low fat–high carbohydrate as compared to high fat–low carbohydrate diets seem to decrease liver fat
and enhance insulin sensitivity in the face of similar isocaloric or hypocaloric total caloric contents.
The deleterious effect of high fat seems to be due to SFAs while PUFA or MUFA containing diets
may be beneficial. Hypercaloric high carbohydrate diets increase liver fat content, but there are no
convincing data to show fructose is worse than glucose, although the metabolism of fructose can be
predicted to have more harmful effects on the liver than glucose. The sources of intrahepatocellular
triglycerides or impact of genetic forms of NAFLD during different diets have not been systematically
studied. Given the high prevalence of both “Metabolic NAFLD”, “PNPLA3 NAFLD” and “TM6SF2
NAFLD” and the associated risks of type 2 diabetes and CVD (“Metabolic NAFLD”) and advanced
liver disease (all forms increase the risk of NASH, cirrhosis and HCC), there is a need for large
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multicenter studies with sufficient numbers of patients to define the composition of a diet which
can prevent or reverse these problems.
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